<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>358</id><JournalTitle>REVIEW ON NOVEL HEART DISORDER-THE FABRY DISEASE</JournalTitle><Abstract>Fabry disease is an x- linked lysosomal disorder which involves cardiac complications like LV, RV hypertrophy and
valvular thickening. This disease also called the "angiokeratoma corporis diffusum universale". As this disease is the
multiorgan system disorder it requires collaboration effort among cardiology, nephrology and neurology. The definitive
diagnosis of fabry disease is the measurement of alpha galactosidase activity in principal WBC (or) in cultured skin fibroblasts
using genetic testing. Generally this disorder is prevented by using the beta blockers and the anti-platelet therapy. A graphical
abstract regarding fabry disease was shown in figure 1</Abstract><Email>vvrao_pharma@yahoo.co.in</Email><articletype>Research</articletype><volume>4</volume><issue>12</issue><year>2013</year><keyword>Lysosomal disorder,Alpha galactosidase enzyme,Genetic testing,Cultured skin fibroblasts</keyword><AUTHORS>Poornachand Tadisetti,Sivasai Kunta,Vivek Reddy T,Venkata Rao Vutla</AUTHORS><afflication>Department of Pharmacy Practice Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India.,Department of Pharmacy Practice Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India.,Department of Pharmacy Practice Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India.,Department of Pharmaceutical Chemistry, Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India</afflication></Article></Articles>